Skip to main content
. 2026 Jul 20;18(14):2331. doi: 10.3390/cancers18142331
ALP Alkaline phosphatase
ARPI Androgen receptor pathway inhibitor
CI Confidence interval
CR Complete response
CRPC Castration-resistant prostate cancer
CT Computed tomography
CTCAE Common Terminology Criteria for Adverse Events
DES Diethylstilbestrol
DICOM Digital Imaging and Communications in Medicine
DSMB Data safety monitoring board
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
EMA European Medicines Agency
FDA Food and Drug Administration
GBq Gigabecquerel
Gy Gray
h Hour
IEC Independent ethics committee
ICRP International Commission on Radiological Protection
IRB Institutional Review Board
LDH Lactate dehydrogenase
mCi Millicurie
mCRPC Metastatic castration-resistant prostate cancer
MBq Megabecquerel
MedDRA Medical Dictionary for Regulatory Activities
min Minute/minimum
MIRD Medical internal radiation dose
MRI Magnetic resonance imaging
ORR Objective response rate
OS Overall survival
OSEM Ordered-subset expectation maximization
PCWG3 Prostate Cancer Working Group 3
PET Positron emission tomography
PR Partial response
PSA Prostate-specific antigen
PSMA Prostate-specific membrane antigen
rADC Radio antibody–drug conjugate
RECIST Response Evaluation Criteria in Solid Tumors
rPFS Radiographic progression-free survival
RLT Radioligand therapy
SD Standard deviation
SOC Standard of care
SPECT Single-photon emission computed tomography
SSE Symptomatic skeletal event
SUV Standardized uptake value
SUVmax Maximum standardized uptake value
Sv Sievert
TEAE Treatment-emergent adverse event